CSPC Innovation Pharmaceutical Co., Ltd. (SHE:300765)
China · Delayed Price · Currency is CNY 34.00
-0.67 (-1.93%)
At close: Feb 6, 2026
SHE:300765 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,042 | 1,928 | 2,485 | 2,571 | 1,790 | 1,289 |
Other Revenue | 52.64 | 52.64 | 53.66 | 55.25 | 60.14 | 28.2 |
| 2,095 | 1,981 | 2,539 | 2,626 | 1,850 | 1,317 | |
Revenue Growth (YoY) | 0.69% | -21.98% | -3.34% | 42.00% | 40.40% | 4.85% |
Cost of Revenue | 1,273 | 1,155 | 1,383 | 1,493 | 1,043 | 584.91 |
Gross Profit | 821.85 | 825.52 | 1,155 | 1,133 | 807.09 | 732.5 |
Selling, General & Admin | 334.28 | 233.37 | 302.21 | 312.29 | 323.91 | 374.09 |
Research & Development | 1,069 | 842.2 | 671.4 | 46.3 | 26.5 | 14.05 |
Other Operating Expenses | 34.97 | 29.57 | 32.73 | 19.92 | 15.75 | 1.63 |
Operating Expenses | 1,440 | 1,102 | 1,001 | 386.31 | 372.19 | 388.36 |
Operating Income | -618.22 | -276.66 | 153.8 | 747.14 | 434.9 | 344.14 |
Interest Expense | -17.64 | -6.37 | -17.63 | -0.22 | -2.83 | - |
Interest & Investment Income | 25.22 | 42.21 | 85.92 | 49.57 | 45.37 | 34.02 |
Currency Exchange Gain (Loss) | 7.44 | 7.44 | 25.17 | 55.21 | -7.07 | -19.66 |
Other Non Operating Income (Expenses) | 15.49 | -0.44 | 1.4 | -0.98 | -1.08 | 5.21 |
EBT Excluding Unusual Items | -587.71 | -233.83 | 248.65 | 850.72 | 469.29 | 363.71 |
Impairment of Goodwill | - | - | - | - | -3.47 | - |
Gain (Loss) on Sale of Investments | -6.02 | -0.89 | - | - | 3.59 | 1.94 |
Gain (Loss) on Sale of Assets | 2.46 | 0.71 | 0.33 | 1.61 | 0.38 | -0.43 |
Asset Writedown | -2.47 | -3.1 | -2.15 | -6.17 | -10.1 | - |
Other Unusual Items | 87.75 | 15.8 | 15.15 | 5.22 | 18.3 | - |
Pretax Income | -506 | -221.3 | 262.14 | 851.37 | 477.99 | 365.22 |
Income Tax Expense | 60.98 | 81.91 | 136.47 | 124.76 | 85.29 | 65.51 |
Earnings From Continuing Operations | -566.98 | -303.21 | 125.67 | 726.61 | 392.7 | 299.71 |
Minority Interest in Earnings | 457.33 | 356.94 | 308.77 | -0.33 | 0.53 | 0.12 |
Net Income | -109.65 | 53.73 | 434.44 | 726.28 | 393.23 | 299.84 |
Net Income to Common | -109.65 | 53.73 | 434.44 | 726.28 | 393.23 | 299.84 |
Net Income Growth | - | -87.63% | -40.18% | 84.70% | 31.15% | 9.75% |
Shares Outstanding (Basic) | 1,391 | 1,399 | 1,397 | 1,337 | 1,337 | 1,178 |
Shares Outstanding (Diluted) | 1,391 | 1,399 | 1,397 | 1,337 | 1,337 | 1,178 |
Shares Change (YoY) | -0.71% | 0.16% | 4.50% | -0.02% | 13.53% | 6.56% |
EPS (Basic) | -0.08 | 0.04 | 0.31 | 0.54 | 0.29 | 0.25 |
EPS (Diluted) | -0.08 | 0.04 | 0.31 | 0.54 | 0.29 | 0.25 |
EPS Growth | - | -87.65% | -42.76% | 84.73% | 15.52% | 2.99% |
Free Cash Flow | -720.27 | -1,713 | 139.72 | 526.67 | 96.67 | 231.33 |
Free Cash Flow Per Share | -0.52 | -1.22 | 0.10 | 0.39 | 0.07 | 0.20 |
Dividend Per Share | 0.020 | 0.020 | 0.267 | 0.069 | 0.069 | 0.036 |
Dividend Growth | -92.50% | -92.50% | 284.29% | - | 94.94% | 49.58% |
Gross Margin | 39.23% | 41.68% | 45.51% | 43.15% | 43.63% | 55.60% |
Operating Margin | -29.51% | -13.97% | 6.06% | 28.45% | 23.51% | 26.12% |
Profit Margin | -5.23% | 2.71% | 17.11% | 27.65% | 21.26% | 22.76% |
Free Cash Flow Margin | -34.38% | -86.47% | 5.50% | 20.05% | 5.23% | 17.56% |
EBITDA | -355.81 | -60.39 | 308.55 | 819.26 | 504.05 | 397.56 |
EBITDA Margin | -16.98% | -3.05% | 12.15% | 31.19% | 27.25% | 30.18% |
D&A For EBITDA | 262.41 | 216.27 | 154.76 | 72.12 | 69.15 | 53.42 |
EBIT | -618.22 | -276.66 | 153.8 | 747.14 | 434.9 | 344.14 |
EBIT Margin | -29.51% | -13.97% | 6.06% | 28.45% | 23.51% | 26.12% |
Effective Tax Rate | - | - | 52.06% | 14.65% | 17.84% | 17.94% |
Revenue as Reported | 2,095 | 1,981 | 2,539 | 2,626 | 1,850 | 1,317 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.